| HIV Infections
Prezcobix vs Reyataz
Side-by-side clinical, coverage, and cost comparison for hiv infections.Deep comparison between: Prezcobix vs Reyataz with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsReyataz has a higher rate of injection site reactions vs Prezcobix based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Reyataz but not Prezcobix, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Prezcobix
Reyataz
At A Glance
Oral
Once daily
HIV-1 protease inhibitor
Oral
Once daily
HIV-1 protease inhibitor
Indications
- HIV Infections
- HIV Infections
Dosing
HIV Infections Adults and pediatric patients >=40 kg: 800 mg/150 mg once daily with food; pediatric patients 25 kg to <40 kg: 675 mg/150 mg once daily with food; pediatric patients 3 years and older, 15 kg to <25 kg: 600 mg/90 mg tablet for oral suspension dispersed in water, once daily with food.
HIV Infections (treatment-naive adults) 300 mg once daily with ritonavir 100 mg once daily with food, or 400 mg once daily with food if unable to tolerate ritonavir
HIV Infections (treatment-experienced adults) 300 mg once daily with ritonavir 100 mg once daily with food; 400 mg once daily with ritonavir 100 mg once daily if taken with both tenofovir DF and H2-receptor antagonist
HIV Infections (pediatric patients 6 to less than 18 years, 15 to less than 35 kg) 200 mg once daily with ritonavir 100 mg once daily with food
HIV Infections (pediatric patients at least 35 kg) 300 mg once daily with ritonavir 100 mg once daily with food
HIV Infections (pediatric patients at least 3 months, 5 to less than 15 kg) 200 mg oral powder once daily with ritonavir 80 mg once daily with food
HIV Infections (pregnant patients) 300 mg once daily with ritonavir 100 mg once daily with food; 400 mg once daily with ritonavir 100 mg once daily during second or third trimester when coadministered with either H2-receptor antagonist or tenofovir DF
Contraindications
- Co-administration with alfuzosin
- Co-administration with carbamazepine, phenobarbital, or phenytoin
- Co-administration with colchicine in patients with renal and/or hepatic impairment
- Co-administration with rifampin
- Co-administration with lurasidone
- Co-administration with pimozide
- Co-administration with dronedarone
- Co-administration with ivabradine
- Co-administration with ranolazine
- Co-administration with ergot derivatives (dihydroergotamine, ergotamine, methylergonovine)
- Co-administration with St. John's wort (Hypericum perforatum)
- Co-administration with elbasvir/grazoprevir
- Co-administration with lomitapide
- Co-administration with lovastatin or simvastatin
- Co-administration with naloxegol
- Co-administration with sildenafil when used for pulmonary arterial hypertension
- Co-administration with orally administered midazolam or triazolam
- Previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, toxic skin eruptions) to any component
- Coadministration with drugs highly dependent on CYP3A or UGT1A1 for clearance where elevated plasma concentrations are associated with serious or life-threatening events (alfuzosin, cisapride, pimozide, orally administered midazolam, triazolam, ergot derivatives, lovastatin, simvastatin, lomitapide, sildenafil for pulmonary arterial hypertension, indinavir, irinotecan, lurasidone when boosted with ritonavir, apalutamide, encorafenib, ivosidenib, elbasvir/grazoprevir, glecaprevir/pibrentasvir)
- Coadministration with strong CYP3A inducers (rifampin, St. John's wort, carbamazepine, phenobarbital, phenytoin, nevirapine)
Adverse Reactions
Most common (>=5%) Diarrhea, nausea, rash, headache, abdominal pain, vomiting
Postmarketing Redistribution of body fat, rhabdomyolysis (with HMG-CoA reductase inhibitors), crystal nephropathy, crystalluria, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms
Most common (>=2%) Nausea, jaundice/scleral icterus, rash, headache, insomnia, dizziness, vomiting, abdominal pain, diarrhea, fever, myalgia, depression, peripheral neurologic symptoms
Serious Cardiac conduction abnormalities (PR interval prolongation, second-degree AV block, third-degree AV block), chronic kidney disease, nephrolithiasis, cholelithiasis
Postmarketing Edema, QTc prolongation, left bundle branch block, pancreatitis, hepatic function abnormalities, cholecystitis, cholestasis, diabetes mellitus, hyperglycemia, arthralgia, interstitial nephritis, granulomatous interstitial nephritis, alopecia, maculopapular rash, pruritus, angioedema
Pharmacology
Darunavir is an HIV-1 protease inhibitor that selectively inhibits cleavage of HIV-1 Gag-Pol polyproteins in infected cells, preventing formation of mature virus particles; cobicistat is a mechanism-based CYP3A inhibitor that increases darunavir systemic exposure without intrinsic antiviral activity.
Atazanavir is an azapeptide HIV-1 protease inhibitor that selectively inhibits virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1-infected cells, preventing formation of mature virions.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Prezcobix
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (1/12) · Qty limit (11/12)
Reyataz
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Prezcobix
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Reyataz
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Prezcobix
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Reyataz
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PrezcobixView full Prezcobix profile
ReyatazView full Reyataz profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.